Assess the Effectiveness and Safety of Lipovirtide Combined With Nucleoside Drugs in HIV-infected Patients.

Prior treatment

• Subjects with an allergy history or hypersensitivity to any component or excipient of the investigational drug;
• Any clinical trials in the 3 months prior to the screening of the trial; 13）Subjects may not be able to complete this study or other investigators' judgment for other reasons.

Other illness

• Subjects with severe opportunistic infections or opportunistic tumors;
• Subjects with confirmed AIDS or in the acute infection stage;
• Hepatitis B virus surface antigen (HBsAg)/hepatitis C virus antibody (HCV-Ab) Positive;
• Subjects with severe and uncontrolled chronic diseases, metabolic diseases, neurological and psychiatric diseases;
• Subjects with a pancreatitis disease history ever before;
• Subjects with a history of drug abuse, alcoholism, or substance misuse;

Lab values

• ALT and/or AST≥5×ULN；
• ALT≥3×ULN and total bilirubin≥2×ULN (direct bilirubin/total bilirubin\>35%;
• GFR\<70ml/min/1.73m2 (estimated from creatinine values based on the CKD-EPI Creatinine 2009 Equation), or creatinine ≥ULN;

Other

• Subjects who are pregnant or lactating women;

• age≥18 years (including the critical value) when signed the informed consent form ,.male or female.
• Untreated, confirmed HIV-1 infected patients;
• HIV RNA viral load≥1000 copies/mL；
• CD4+ T cell counts≥200 cells/mm3；
• Subjects who have no plans for conception within the 2 weeks prior to screening and 3 months after the end of the trial, and who agree to use effective non-pharmacological contraceptive measures during the trial;
• Sign informed consent prior to the test and fully understand the purpose, nature, methods, and possible adverse reactions, and be willing to participate in the study.